Press Releases

Out-of-the-box Solution for Digital Signage Based on MSI Windbox II

NUREMBERG, Germany--(BUSINESS WIRE)-- spo-comm, MSI Industrial Partner and mini PC solution provider for Germany, Austria and Switzerland, announces a partnership with friendlyway, the leading provider for touch screen kiosks, digital signage solution and internet kiosk software.

The cooperation aims at providing a universal and pragmatic solution for digital signage. friendlyway will base its starter kit "Digital Signage Player Package Regular Edition" on MSI Windbox II and with friendlyway player 9 pre-installed. To get started, users only need to connect to LAN or WLAN and to register the player at friendlyway network services.

The solution leverages the benefits of Windbox II. The flat, fanless system offers a VESA holder to be fixed to most types of flat screens. With a maximum of 17 Watt power consumption, Digital Signage Player Package Regular Edition is a true Green IT device.

"With this product, users will benefit from the high-quality strategy of both spo-comm and friendlyway and our year-long experience in the field of digital signage" said Michael Sporrer, managing director of spo-comm. "This enables our customers to concentrate on their core business: The digital presentation of content."

"With MSI Windbox we can act more flexible in price-sensitive digital signage projects with medium demands for player capabilities", said Klaus Trox, Spokesman of the Managing Board of friendlyway.

About friendlyway AG:

friendlyway specializes in development and marketing of standard software and system solutions for digital advertising displays (digital signage) and interactive kiosk systems. friendlyway AG has developed technology solutions for over 10 years and has an installation base of over 25,000 throughout Europe, Asia and the United States. For more information, please visit www.friendlyway.com.

About spo-comm GmbH:

spo-comm provides mini-pc solutions for industry and retail market in Germany and Europe. Besides hardware, spo-comm also offers software solutions, services and supply chain management for mini-pcs. Founded in 2002, spo-comm has a large network of partners worldwide. For more information, please visit www.spo-comm.de.

    Source: spo-comm GmbH

LAS VEGAS, NV -- (MARKET WIRE) -- 12/02/09 -- Atlantis Internet Group Corp. (PINKSHEETS: ATIG) announced today that it has obtained a license from EMI Music Publishing allowing it to offer EMI's entire music library consisting of over 1,500,000 songs for Atlantis Internet Group's new Jukebox Slot machines. The patent pending Jukebox Slots allows casino players to listen to their favorite tunes while playing Slots, Electronic Table and Tournament games.

"Jukebox Slots offers the gaming industry a refreshing new twist with slots, electronic table games, tournament games and music all in one machine; we call it a 'Casino in a Casino,'" said Donald L. Bailey, president and CEO of Atlantis Internet Group.

ATIG started with Hitsville Ventures, LLC to offer music from the largest group of Motown Entertainers since Berry Gordy's heyday, and contracted with ID Interactive, LLC, one of the gaming industries' most innovative slot development companies, to develop Jukebox Slots. ID Interactive currently has slots in Indian casinos nationwide with over 100 vendor gaming licenses in Indian casinos. ID Interactive will also distribute the new Jukebox Slots product. The two companies have signed a term sheet mapping out a potential future merger.

Jukebox Slots will be featured on the Indian version of ATIG's Casino Gateway Network, the "Tribal Gateway Network" -- a gaming network linking Indian casinos nationwide offering popular Class III and Class II games such as Wide Area Progressive Slots, Poker, Keno, Lotto Games, Blackjack, Bango Football and more. ATIG recently received an opinion from the National Indian Gaming Commission (NIGC) allowing it to operate its gaming network in over 450 Indian casinos nationwide.

"In the development of Jukebox Slots, we have selected the best minds in the music industry, EMI and Hitsville Ventures, LLC, and ID Interactive, LLC, to offer an innovative slot product. ID Interactive's software is widely used by the industry's leading slot manufacturers in the U.S. and in international gaming jurisdictions," said Bailey.

About Atlantis Internet Group Corp.

Utilizing an innovative development team and licensed gaming executives to oversee its state-of-the-art online gaming and slot machine products, Atlantis Internet Group Corp. is bridging the gap between traditional gaming casinos and online gaming. Atlantis Internet Group Corp. is one of the first companies to interface with online games and player tracking systems found on traditional floor slot machines.

Internet users can play-for-fun games including blackjack, roulette, craps, and more at http://www.AtlantisInternetGroup.com. The games utilize industry leading technology. In addition, the web site features links to Atlantis Internet Group clients, corporate information, and descriptions of products the company offers.

Forward-Looking Statements

Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1127810

Contact:
Linda Bailey
717-652-8015
http://www.AtlantisInternetGroup.com

HOUSTON, Dec. 2 /PRNewswire-FirstCall/ -- Far East Energy Corporation (OTC Bulletin Board: FEEC) announced today that gas production in the Shouyang Block of Shanxi Province, China, has now risen to 500,000 cubic feet, or 500 Mcf per day. Previously, on November 30, Far East announced that gas production from the Shouyang Block had exceeded 400,000 cubic feet per day.

"This acceleration in gas production is not unexpected," said Garry Ward, Senior Vice President of Engineering, "but the rapidity of the increase is a surprise, and a pleasant one."

Far East does note that, as in any oil and gas exploration activity, certain events such as normal fluctuations in gas flow, wells being taken offline for workovers, etcetera, could cause reductions in the amount of gas being produced.

About Far East Energy Corporation

Based in Houston, Texas, with offices in Beijing, Kunming, and Taiyuan City, China, Far East Energy Corporation is focused on CBM exploration and development in China.

Statements contained in this press release that state the intentions, hopes, beliefs, anticipations, expectations or predictions of the future of Far East Energy Corporation and its management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. It is important to note that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties. Actual results could differ materially from those projected in such forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include: pipelines may not be constructed or their routes may differ from those mentioned; pipeline and local distribution/CNG companies may decline to purchase or take our gas; the gas produced at our wells may not increase to commercially viable quantities or may decrease; we may have insufficient capital to develop the Shouyang field; weather may significantly delay the planned drilling program; wells may be damaged or adversely impacted during the production process, resulting in decreases in the amount of gas produced, or that can be produced; certain proposed transactions with Arrow may not close on a timely basis or at all, including due to a failure to satisfy closing conditions or otherwise; the anticipated benefits to us of transactions with Arrow may not be realized; the final amounts received by us from Arrow may be different than anticipated; Chinese Ministry of Commerce (MOFCOM) may not approve the extensions of the Qinnan Production Sharing Contract (Qinnan PSC) on a timely basis or at all; PetroChina or MOFCOM may require certain changes to the terms and conditions of the Qinnan PSC in conjunction with their approval of any extension; our lack of operating history; limited and potentially inadequate management of our cash resources; risk and uncertainties associated with exploration, development and production of CBM; expropriation and other risks associated with foreign operations; disruptions in capital markets effecting fundraising; matters affecting the energy industry generally; lack of availability of oil and gas field goods and services; environmental risks; drilling and production risks; changes in laws or regulations affecting our operations, as well as other risks described in our Annual Report on Form 10-K for 2008 and subsequent filings with the Securities and Exchange Commission.

SOURCE Far East Energy Corporation

LOS ANGELES, Dec. 2 /PRNewswire-USNewswire/ -- Discovery Institute has filed a lawsuit against the California Science Center (the "Center") for unlawfully refusing to disclose public documents requested by Discovery Institute under the California Public Records Act.

Discovery Institute filed the public documents request on October 9, 2009, following the Center's October 6, 2009 cancellation of a contract with the American Freedom Alliance (AFA) to screen a pro-intelligent design video, Darwin's Dilemma, at the California Science Center's IMAX Theatre on October 25, 2009.

On November 2, 2009, the Center released 44 pages of documents claiming to have disclosed "all documents" and that "no documents have been withheld," apart from a few e-mail addresses that were redacted.

"California Science Center's claims are not true, and we know for a fact that e-mail communications exist, including communications with the Smithsonian Institution, that should have been disclosed in response to our public documents request but weren't, showing clear violation of California's Public Records Act," said Casey Luskin, Program Officer in Public Policy and Legal Affairs at the Discovery Institute.

"The Center withheld public communications by decision makers who cancelled the contract with AFA," said Luskin. "We believe the reason the California Science Center withheld these public documents is simple: the e-mails show evidence of discrimination against the pro-intelligent design viewpoint."

Discovery Institute's lawsuit follows a separate lawsuit filed against the California Science Center by the AFA for cancelling its contract to show the pro-intelligent design video.

"We also have evidence that the California Science Center had written communications with the Smithsonian Institution expressing angst over the AFA's pro-intelligent design event," explained Luskin. "Yet not a single e-mail, letter, or other document disclosed by the California Science Center mentions the Smithsonian, even though our public documents request specifically asked for documents referencing the 'Smithsonian'."

The California Public Records Act guarantees the public "access to information concerning the conduct of the people's business is a fundamental and necessary right."

"If the Center wrongfully refused to disclose certain now-known public documents, how many other public documents remain to be uncovered that evidence the California Science Center's viewpoint discrimination?" asked Luskin. "We hope this lawsuit will answer that question."

The lawsuit was filed in State Superior Court in Los Angeles County. Docket number: BS123905.

SOURCE Discovery Institute

Predictive Assay First to Combine Both Protein and DNA Urinary Biomarkers to Optimize Assay Performance

LEXINGTON, Mass.--(BUSINESS WIRE)-- Predictive Biosciences today announced that Company scientists will be presenting a novel multi-analyte approach to the development of a non-invasive, urine-biomarker based diagnostic assay during the 10th Annual Meeting of the Society of Urologic Oncology (SUO). The research was done under collaboration agreements with Lahey Clinic Medical Center and Mayo Clinic. This pioneering scientific research represents the first example of protein and DNA biomarkers being combined into one assay to optimize performance. The SUO meeting is being held December 2-4, 2009 at the Natcher Conference Center of the National Institutes of Health (NIH) in Bethesda, Maryland.

Predictive's unique approach to diagnosing and monitoring bladder cancer will be highlighted in a poster presentation titled "Multi-Analyte Diagnostic Readout (MADR): Combining Protein and DNA Markers to Maximize Clinical Performance," during Poster Session I, which takes place on Thursday, December 3, from 4:00 p.m. to 6:00 p.m. E.T. Cecilia A. Fernandez, Ph.D., senior scientist at Predictive Biosciences and first author, will present the poster, which demonstrates how the performance of Predictive's bladder cancer assay was improved by utilizing both Matrix Metalloproteinase (MMP) biomarkers and Fibroblast Growth Factor Receptor 3 (FGFR3) biomarkers, leveraging the sensitivity and specificity achieved by each. Predictive's proprietary MADR method is an extension of its Clinical Intervention Determining Diagnostic approach - termed CIDD - to the non-invasive management of bladder and other cancers.

The poster first illustrates how Predictive's assay, by utilizing MMPs detected in urine as monitors of disease-free status, was able to identify with high confidence -- as measured by negative predictive value (NPV) -- the bladder cancer participants who did not have cancer recurrence at the time of evaluation. The poster goes on to demonstrate that by adding a Real Time PCR (polymerase chain reaction) based assay to detect FGFR3 mutations as monitors of disease recurrence, Predictive was able to further increase the assay's NPV, with no reduction in specificity.

"To our knowledge, we are the first and only company to combine both protein and DNA biomarkers into one assay to deliver both high negative and high positive predictive values for the absence or presence of cancer, respectively," commented Anthony P. Shuber, co-founder and chief technology officer for Predictive Biosciences.

FGFR3 gene mutations, detectable in the urine of bladder cancer patients, have been shown to be associated with early stage/early grade bladder cancer with up to 70 percent of low grade tumors showing mutation. Predictive believes that the inclusion of this binary DNA biomarker in its bladder cancer assay will also help to detect lower stage/grade bladder cancers which have been difficult to detect with other biomarkers.

Mr. Shuber continued, "Carried forward into the clinical setting, we are aiming to provide urologists with a non-invasive diagnostic tool that we anticipate will initially be used in tandem with current standard-of-care approaches such as cystoscopy, cytology and upper urinary tract imaging. Ultimately, our goal would be for physicians to use the test as an actionable tool prior to cystoscopy. We believe it will allow them to confidently triage patients by those who are highest risk and require accelerated intervention, those who are average risk and should receive standard-of-care, and importantly, those who are at very low risk and can forgo cystoscopy."

Mr. Shuber will accompany Dr. Fernandez at the SUO poster presentation.

About Predictive Biosciences

Leveraging its portfolio of patented biomarkers and clinical algorithms, Predictive Biosciences is pioneering intervention diagnostic assays for informed cancer management(TM). Predictive Biosciences' tests will enable physicians to reliably determine the presence or absence of cancer. This information, incorporated into current standard clinical practice, should lead to more effective utilization of existing diagnostic tools and ultimately better outcomes for patients. Predictive Biosciences' first assays are designed to detect urinary biomarkers fundamentally associated with the physiological changes resulting from cancer development and progression. The initial focus for these tests will be the growing cancer survivor population and the large number of individuals undergoing clinical workups for cancer. Predictive Biosciences was launched in 2006 and is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. For more information and partnership inquiries, visit Predictive Biosciences' website at www.predictivebiosci.com.

    Source: Predictive Biosciences